MS Boon: Many Drugs On The Way, But Will Payors Swallow The Cost?
Several new drugs for multiple sclerosis could launch within the next two years, but amid escalating drug costs, payors are taking a harder look at the therapeutic category. New drugs will face increasing reimbursement hurdles, as payors implement the first prior authorization and step therapy protocols and look for ways to implement further cost reductions.
You may also be interested in...
FDA “has not to date had any questions that would indicate our application is off track,” CEO Wheeler says as Momenta and partner Sandoz gear up for the launch.
Wall Street is mixed on whether Teva’s newly approved three-times-weekly formulation will protect its MS blockbuster franchise.
Merck KGAA’s $13 billion acquisition of Serono in 2006 created an unwieldy pharmaceutical organization further hobbled by expensive clinical setbacks. Seven years later, driven by new leadership, it is in the midst of an overdue transformation.